1026201-52-4 Usage
General Description
5-Bromoimidazo[1,2-a]pyridine-2-carboxylic acid is a chemical compound with the molecular formula C8H5BrN3O2. It is a heterocyclic organic compound containing a bromine atom and a carboxylic acid group attached to an imidazo[1,2-a]pyridine ring. This chemical is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also used as a reagent in organic chemical reactions and as a precursor in the preparation of various functionalized derivatives. 5-Bromoimidazo[1,2-a]pyridine-2-carboxylic acid is known for its importance in medicinal chemistry and is a versatile intermediate in the synthesis of biologically active compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1026201-52-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,6,2,0 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1026201-52:
(9*1)+(8*0)+(7*2)+(6*6)+(5*2)+(4*0)+(3*1)+(2*5)+(1*2)=84
84 % 10 = 4
So 1026201-52-4 is a valid CAS Registry Number.
1026201-52-4Relevant articles and documents
JAK kinase inhibitor and application thereof
-
Paragraph 0101-0103; 0108-0112, (2020/11/23)
The invention discloses a JAK kinase inhibitor and an application thereof. The JAK kinase inhibitor is a compound represented by a formula I or a stereoisomer, a tautomer or pharmaceutically acceptable salt or a solvate or a prodrug of the compound; the invention further provides the application of the compound represented by the formula I in preparation of drugs for preventing or treating JAK kinase related diseases, and in particular, relates to the application in preparing medicines for preventing and/or treating diseases related to cartilage degeneration and bone and/or joint degeneration,diseases related to inflammation or immune response, endotoxin-driven disease states, cancers and organ transplantation rejection.
HCV NS3 PROTEASE INHIBITORS
-
Page/Page column 52, (2008/12/05)
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
